Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action
Abstract Background Clozapine has remarkable efficacy on both negative and cognitive symptoms of schizophrenia due to its slight activation of NMDA receptor. In fact, much evidence to the contrary. NMDAR is a complex containing specific binding sites, which are regulated to improve negative symptoms...
| Үндсэн зохиолчид: | , , , , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | English |
| Хэвлэсэн: |
BMC
2020-03-01
|
| Цуврал: | BMC Psychiatry |
| Нөхцлүүд: | |
| Онлайн хандалт: | http://link.springer.com/article/10.1186/s12888-020-02509-z |